Mantle Cell Lymphoma Specialty Channel

Mantle Cell Lymphoma

Specialty Channel

Quiz

Ibrutinib Plus Venetoclax for Patients With TP53-Mutated MCL

10/11/2024

According to results presented at ASCO 2024 from the SYMPATICO study population in patients with MCL with TP53 mutations, the combination of ibrutinib plus venetoclax increased overall survival to ___ months for all 74 patients. 50473230

According to results presented...

10/11/2024

Oncology

Quiz

FDA Approval of Lisocabtagene Maraleucel for MCL

07/01/2024

Oncology

FDA Approval

FDA Approves Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma

06/03/2024

Amber Denham

The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.

The U.S. Food and Drug...

06/03/2024

Oncology

Quiz

Efficacy of Rituximab Maintenance After ASCT Among Patients With Mantle Cell Lymphoma

05/30/2024

Oncology

News

Rituximab Maintenance After ASCT Yields Long-Term Benefits for Patients With Mantle Cell Lymphoma

03/05/2024

Jordan Kadish

According to a long-term follow-up of the LYMA trial, rituximab maintenance following autologous stem cell transplantation continued to demonstrate benefits to efficacy and safety outcomes among first-line patients with mantle cell lymphoma.

According to a long-term...

03/05/2024

Oncology

News

Novel Prognostic Models Provide Valuable Guidance for Mantle Cell Lymphoma Treatment Strategy

03/01/2024

Jordan Kadish

Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.

Advances in prognostic models...

03/01/2024

Oncology

News

BTK Inhibitor and T-Cell Redirecting Immunotherapy Combination Shows Promise for Patients With R/R MCL

02/28/2024

Amber Denham

According to a phase 2 study, the combination of time-limited ibrutinib and T-cell redirecting immunotherapy demonstrates promising results among patients with relapsed/refractory mantle cell lymphoma.

According to a phase 2 study,...

02/28/2024

Oncology

News

MRD-Driven Venetoclax, Lenalidomide, and Rituximab Combo Demonstrates Efficacy Among Patients With R/R Mantle Cell Lymphoma

02/23/2024

Amber Denham

Minimal residual disease-driven venetoclax, lenalidomide, and rituximab is a feasible and tolerable treatment regimen for patients with relapsed/refractory mantle cell lymphoma, according to results from a phase 1b/2 study.

Minimal residual disease-driven...

02/23/2024

Oncology

Quiz

Efficacy of Rituximab Maintenance Among Elderly Patients With Previously Untreated MCL

02/22/2024

Oncology

News

MRD Status Predicts Efficacy of Rituximab Maintenance Among Elderly Patients With MCL

01/24/2024

Mellanie True Hills ;

Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.

Minimal residual disease status...

01/24/2024

Oncology

Quiz

Treating R/R Mantle Cell Lymphoma With Orelabrutinib

01/23/2024

According to a multicenter, open-label phase 1/2 study, orelabrutinib demonstrated efficacy and safety among patients with R/R mantle cell lymphoma (MCL), who achieved an overall response rate of ___.

According to a multicenter,...

01/23/2024

Oncology

News

FDA Approval

FDA Approves Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma

06/03/2024

Amber Denham

The U.S. Food and Drug...

06/03/2024

Oncology

News

Rituximab Maintenance After ASCT Yields Long-Term Benefits for Patients With Mantle Cell Lymphoma

03/05/2024

Jordan Kadish

According to a long-term...

03/05/2024

Oncology

News

Novel Prognostic Models Provide Valuable Guidance for Mantle Cell Lymphoma Treatment Strategy

03/01/2024

Jordan Kadish

Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.

Advances in prognostic models...

03/01/2024

Oncology

News

BTK Inhibitor and T-Cell Redirecting Immunotherapy Combination Shows Promise for Patients With R/R MCL

02/28/2024

Amber Denham

According to a phase 2 study,...

02/28/2024

Oncology

News

MRD-Driven Venetoclax, Lenalidomide, and Rituximab Combo Demonstrates Efficacy Among Patients With R/R Mantle Cell Lymphoma

02/23/2024

Amber Denham

Minimal residual disease-driven...

02/23/2024

Oncology

News

MRD Status Predicts Efficacy of Rituximab Maintenance Among Elderly Patients With MCL

01/24/2024

Mellanie True Hills ;

Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.

Minimal residual disease status...

01/24/2024

Oncology

News

Rituximab, Lenalidomide, and Ibrutinib Regimen Exhibits Safe and Effective Outcomes Among Patients With R/R MCL

11/28/2023

Mellanie True Hills ;

The R21 regimen, consisting of rituximab, lenalidomide, and ibrutinib, exhibited safe and effective outcomes among patients with R/R mantle cell lymphoma, including those with high-risk features.

The R21 regimen, consisting of...

11/28/2023

Oncology

News

Brexucabtagene Autoleucel vs Standard-Of-Care Treatment for Patients With R/R MCL

11/28/2023

Mellanie True Hills ;

According to a comparative analysis of the SCHOLAR-2 and ZUMA-2 trials, brexucabtagene autoleucel showed significant survival benefits compared to the standard-of-care treatment for patients with R/R mantle cell lymphoma after covalent BTK...

According to a comparative...

11/28/2023

Oncology

News

Bridging and Salvage Radiotherapy Significantly Improved In-Field Control Among Patients With R/R MCL

11/06/2023

Mellanie True Hills ;

The use of radiotherapy as a bridging and salvage approach significantly improved in-field control outcomes and safety in the peri-CAR T setting among patients with R/R mantle cell lymphoma.

The use of radiotherapy as a...

11/06/2023

Oncology

News

Anti-CD19 CAR T-Cell Therapy Demonstrates Feasibility Among Patients With MCL With Secondary CNS Involvement

11/06/2023

Mellanie True Hills ;

Anti-CD19 chimeric antigen receptor T-cell therapy was demonstrated to be feasible among patients with mantle cell lymphoma with secondary central nervous system involvement.

Anti-CD19 chimeric antigen...

11/06/2023

Oncology

Interactive Features

Quiz

FDA Approval of Lisocabtagene Maraleucel for MCL

07/01/2024

Oncology

Quiz

Efficacy of Rituximab Maintenance After ASCT Among Patients With Mantle Cell Lymphoma

05/30/2024

Oncology

Quiz

Efficacy of Rituximab Maintenance Among Elderly Patients With Previously Untreated MCL

02/22/2024

Oncology

Quiz

Treating R/R Mantle Cell Lymphoma With Orelabrutinib

01/23/2024

According to a multicenter,...

01/23/2024

Oncology

Quiz

Treating MCL With Bridging and Salvage Radiotherapy

12/05/2023

True or False: According to findings from a retrospective study, the use of radiotherapy (RT) as a bridging and salvage approach significantly improved in-field control outcomes, but increased toxicity among patients with relapsed/refractory...

True or False: According to...

12/05/2023

Oncology

Quiz

Anti-CD19 CAR T-Cell Therapy for MCL With SCNS Involvement

12/01/2023

True or False: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy did not demonstrate feasibility among patients with mantle cell lymphoma (MCL) with secondary central nervous system (SCNS) involvement.

True or False: Anti-CD19...

12/01/2023

Oncology

Quiz

Treating R/R MCL With PI3Kδ Inhibitor Parsaclisib

11/27/2023

True or False: Findings from the phase 2 CITADEL-205 trial indicated that PI3Kδ inhibitor parsaclisib demonstrated significant clinical benefits and a manageable safety profile among patients with R/R mantle cell lymphoma with no prior BTK...

True or False: Findings from the...

11/27/2023

Oncology

Quiz

Prognostic Value of Single Nucleotide Polymorphism for iNHL and MCL

11/21/2023

Results from a 5-year follow-up study found that gene polymorphisms, particularly the _____ single nucleotide polymorphism (SNP), demonstrated prognostic value for disease outcomes among patients with indolent non-Hodgkin lymphomas and mantle...

Results from a 5-year follow-up...

11/21/2023

Oncology

Quiz

Allogeneic Stem Cell Transplantation for R/R Mantle Cell Lymphoma

11/14/2023

According to findings from an extended follow-up study on allogeneic stem cell transplantation (alloSCT) for R/R mantle cell lymphoma, which of the following statements is true?

According to findings from an...

11/14/2023

Oncology

Quiz

Efficacy of Pirtobrutinib for Heavily-Pretreated MCL

10/30/2023

Findings from the BRUIN trial indicated that BTK inhibitor pirtobrutinib demonstrated durable and encouraging efficacy and safety outcomes among patients with heavily pretreated MCL after covalent BTK inhibitor treatment, with patients...

Findings from the BRUIN trial...

10/30/2023

Oncology

Recent News

FDA Approval

FDA Approves Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma

06/03/2024

Amber Denham

The U.S. Food and Drug...

06/03/2024

Oncology

News

Rituximab Maintenance After ASCT Yields Long-Term Benefits for Patients With Mantle Cell Lymphoma

03/05/2024

Jordan Kadish

According to a long-term...

03/05/2024

Oncology

News

Novel Prognostic Models Provide Valuable Guidance for Mantle Cell Lymphoma Treatment Strategy

03/01/2024

Jordan Kadish

Advances in prognostic models can help guide treatment strategy for patients with mantle cell lymphoma, according to an analysis by The North American Mantle Cell Lymphoma Consortium.

Advances in prognostic models...

03/01/2024

Oncology

News

BTK Inhibitor and T-Cell Redirecting Immunotherapy Combination Shows Promise for Patients With R/R MCL

02/28/2024

Amber Denham

According to a phase 2 study,...

02/28/2024

Oncology

News

MRD-Driven Venetoclax, Lenalidomide, and Rituximab Combo Demonstrates Efficacy Among Patients With R/R Mantle Cell Lymphoma

02/23/2024

Amber Denham

Minimal residual disease-driven...

02/23/2024

Oncology

News

MRD Status Predicts Efficacy of Rituximab Maintenance Among Elderly Patients With MCL

01/24/2024

Mellanie True Hills ;

Minimal residual disease status held value in predicting the efficacy of rituximab maintenance among elderly patients with previously untreated mantle cell lymphoma.

Minimal residual disease status...

01/24/2024

Oncology

News

Rituximab, Lenalidomide, and Ibrutinib Regimen Exhibits Safe and Effective Outcomes Among Patients With R/R MCL

11/28/2023

Mellanie True Hills ;

The R21 regimen, consisting of rituximab, lenalidomide, and ibrutinib, exhibited safe and effective outcomes among patients with R/R mantle cell lymphoma, including those with high-risk features.

The R21 regimen, consisting of...

11/28/2023

Oncology

News

Brexucabtagene Autoleucel vs Standard-Of-Care Treatment for Patients With R/R MCL

11/28/2023

Mellanie True Hills ;

According to a comparative...

11/28/2023

Oncology

News

Bridging and Salvage Radiotherapy Significantly Improved In-Field Control Among Patients With R/R MCL

11/06/2023

Mellanie True Hills ;

The use of radiotherapy as a bridging and salvage approach significantly improved in-field control outcomes and safety in the peri-CAR T setting among patients with R/R mantle cell lymphoma.

The use of radiotherapy as a...

11/06/2023

Oncology

News

Anti-CD19 CAR T-Cell Therapy Demonstrates Feasibility Among Patients With MCL With Secondary CNS Involvement

11/06/2023

Mellanie True Hills ;

Anti-CD19 chimeric antigen receptor T-cell therapy was demonstrated to be feasible among patients with mantle cell lymphoma with secondary central nervous system involvement.

Anti-CD19 chimeric antigen...

11/06/2023

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology